<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405963</url>
  </required_header>
  <id_info>
    <org_study_id>20101183</org_study_id>
    <nct_id>NCT01405963</nct_id>
  </id_info>
  <brief_title>Double-blind, Multiple Dose Study in Subjects With Mild Atopic Asthma</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the late asthmatic response, safety and tolerability
      of AMG 157 following multiple intravenous (IV) dose administration in subjects with mild
      atopic asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate late asthmatic response, as measured by area under the curve (AUC) in the forced expiratory volume (FEV1) in 1 sec btwn 3 &amp; 7 hrs after an allergen inhalation challenge in mild atopic asthmatic subjects</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate late asthmatic response, as measured by the max percentage fall in the forced expiratory volume (FEV1) in 1 sec btwn 3 &amp; 7 hrs after an allergen inhalation challenge in mild atopic asthmatic subjects</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate early asthmatic response, as measured by area under the curve (AUC) in forced expiratory volume (FEV1) in 1 sec btwn 0 &amp; 2 hrs after an allergen inhalation challenge in mild atopic asthmatic subjects</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate early asthmatic response, as measured by the max percentage fall in forced expiratory volume (FEV1) in 1 sec btwn 0 &amp; 2 hrs after an allergen inhalation challenge in mild atopic asthmatic subjects</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the area under the plasma concentration curve versus time of AMG 157 after multiple dose administration in subjects with mild atopic asthma</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the number of adverse events per subject, after multiple dose administration of AMG 157 in subjects with mild atopic asthma</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator administered as a multiple IV doses in subjects with mild atopic asthma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 157 Matching Placebo</intervention_name>
    <description>Matching placebo administered as multiple IV doses in subjects with mild atopic asthma</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 157</intervention_name>
    <description>One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.</description>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with history of mild atopic asthma between 18 and 60
             years-of-age

          -  Body mass index (BMI) between 18 and 35 kg/m2

          -  Normal or clinically acceptable physical examination (PE), clinical laboratory values,
             and ECG; clinically acceptable PE includes history of mild atopic asthma

          -  Used only inhaled short-acting Î²2-agonists infrequently to treat asthma

          -  No current exposure to allergens to which subject experiences asthmatic responses

          -  No other lung disease, exacerbations of asthma or lower respiratory tract infections
             for at least 6 weeks prior to screening

          -  Positive skin prick test to common aeroallergens at screening

          -  Additional inclusion criteria apply

        Exclusion Criteria:

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluation, procedures or completion;

          -  History or current medical conditions that are contraindicated for methacholine
             challenge, such as myocardial infarction or stroke within previous 3 months, known
             cardiac disease, uncontrolled hypertension and aortic or cerebral aneurysm

          -  Evidence of active or suspected bacterial, viral, fungal or parasitic infections
             within past 6 weeks

          -  Subject has know type I/II diabetes

          -  History of residential exposure to tuberculosis or has a positive PPD or QuantiFERON
             test within 4 weeks before randomization

          -  Subject who has history of malignancy of any type within 5 years prior to enrollment

          -  Subjects tested positive for drugs/alcohol or nicotine use at screening

          -  Subjects tested positive for HIV, Hep B or Hep C

          -  Additional exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>AMG 157</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

